摘要
目的:研究利奈唑胺在危重症患者中的药动学药效学特点。方法:9例革兰阳性球菌感染的危重症患者,其中3例接受连续性肾脏替代治疗(CRRT),在1 h内静脉滴注利奈唑胺600 mg,收集患者用药前后的血液样本进行血药浓度测定。通过DAS 2.0软件计算药动学参数,结合微生物学对其药效学指标进行评价。结果:与非CRRT组患者相比,CRRT组患者中的半衰期显著缩短,且给药3 d内的谷浓度值均低于CRRT组。7例患者的PK-PD参数达标情况与实际临床治疗结果相吻合。结论:利奈唑胺在危重症患者体内的药动学参数个体差异较大。CRRT患者可能会存在机体内药物暴露量不足问题,应根据PK/PD参数为此类患者制定合理的给药方案。
Objective: To study the pharmacokinetic and pharmacodynamic profile of linezolid in critically ill patients.Methods: Each of 9 critically ill patients caused by Gram-positive cocci infection(3 of whom received CRRT) was administered by i.v.infusion of a dose of 600 mg in 1 h.Blood samples of the patients were collected before and after dosing for blood drug concentration determination.Pharmacokinetic parameters calculated by DAS2.0 in combination of the microbiology was used to evaluate the pharmacodynamic indicators.Results: The halflife was significantly shortened in the CRRT group compared with non-CRRT group,and the trough concentration values within 3 days of administration were lower than those in the CRRT group.The parameters of PK-PD of 7 patients were in accordance with the results of actual clinical treatment.Conclusions: A high variability of the pharmacokinetic parameters of linezolid was observed.The Patients received CRRT may have insufficient drug exposure in vivo and a reasonable dosing regimen should be established for such patients based on PK/PD parameters.
作者
张永煌
邱季
董一曼
史天陆
ZHANG Yong-huang;QIU Ji;DONG Yi-man;SHI Tian-lu(Department of Pharmacy,Hefei Binhu Hospital,Hefei 230601,China;The First Hospital Affiliated to University of Science and Technology of China,Hefei 230022,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第23期2756-2760,共5页
Chinese Journal of New Drugs
